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Abstract
Background: The pp-Whipple procedure requires extensive preparation. The conventional preparation technique is
done with scissors for dissection and ligatures, and with clips and sutures for hemostasis. This procedure is very
time-consuming and requires numerous changes of instruments. The LigaSure™ device allows dissection and
hemostasis for preparation with one instrument. Up to now there has been no comparison of the two techniques
with regard to operating time and the patients’ outcome. It is still unclear which technique has the optimal
benefit/risk ratio for the patient.
Methods/Design: A single-center, randomized, single-blinded, controlled superiority trial to compare two different
techniques for dissection in a pp-Whipple procedure. 102 patients will be included and randomized pre-
operatively. All patients aged 18 years or older scheduled for primary elective pp-Whipple procedure who signed
the informed consent will be included. The primary endpoint is the operating time of the randomized technique.
Control Intervention: Conventional dissection technique; experimental intervention: LigaSureTM dissection
technique. Duration of study: Approximately 15 months; follow up time: 3 years. The trial is registered at German
ClinicalTrials Register (DRKS00000166).
Background
The procedure was originally described by Alessandro
Codivilla in 1898, A.O. Whipple improved it in 1935.
The Whipple procedure is the standard method for
therapy of cancerous tumours, inflammation and steno-
sis near the head of the pancreas. In the classic Whip-
ple-procedure (c-Whipple) the head of the pancreas, the
duodenum, the regional lymph nodes, the gastric
antrum, the gallbladder, and the distal bile duct are
removed. The pylorus-preserving-Whipple procedure
(pp-Whipple) was established by Traverso and Longmire
in 1978. During this procedure the gastric antrum is not
removed. In recent years the pp-Whipple procedure is
preferred because several studies have shown that the
classic Whipple procedure is not superior to the pp-
Whipple procedure regarding the oncological outcome
or peri- and postoperative complication rates [1-5].
About 300 patients are operated on following the pp-
Whipple procedure at the department each year. As
the pancreas is fed by many vessels [6], it is necessary
to use lots of ligatures, clips and sutures for hemostasis
after dissection. This dissection technique is very time-
consuming and requires numerous changes of instru-
ments. The use of high-frequency feedback-controlled
electrothermal bipolar vessel sealant technology,
known as the LigaSure™ Vessel Sealing System
(LVSS), is a new alternative for dissection and hemos-
tasis. The bipolar vessel dissection devices require no
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[7-10]. The current is provided by a special HF-genera-
tor and contains a very high capacity with a low vol-
tage. The body’s proteins, such as collagen and elastin,
are converted so a permanently sealed zone results. As
o n l yt h et i s s u eb e t w e e nt h eb r a n c h e si ss e a l e d ,l a t e r a l
thermic tissue damages can be limited to a minimum.
Several authors describe a tendency of reduced intrao-
perative blood loss and transfused blood preservations
[11-13]. Other trials show reduced operating time
using the LVSS in several surgical procedures, such as
thyroid, gynecology, urology and haemorrhoidectomy
surgery [9,11,13,14].
Correct dissection in the operation field is very impor-
tant to avert secondary bleeding or other complications,
which might cause re-operation or elevate the patients’
morbidity and mortality [15].
Methods/Design
Aim of study
The comparison of LVSS versus conventional dissection
technique in pylorus-preserving pancreatoduodenectomy
regarding operation time and complication rates.
Number of patients needed
The sample size calculation is based on a two sided t-
test for differences with respect to the primary endpoint.
The data evaluation and comparison of seven patients
operated on with the LVSS versus seven patients oper-
ated on with the conventional dissection technique
showed a reduction of operating time of 40 minutes in
the LVSS group. An evaluation of all pp-Whipple opera-
tions in 2010 (138 operations) showed a mean operating
time of 300 min with a standard deviation of 66 min-
utes. If the difference in operating time is 40 minutes,
t h e r ew i l lb ea n8 0 %( 1 - b)c h a n c et h a tat r i a li n v o l v i n g
88 patients (44 per group) could detect a significant dif-
f e r e n c ea ta na l p h al e v e lo f5 % s( S A S9 . 1p r o cp o w e r ) .
To compensate possible drop outs 14 patients (15%)
more will be randomized. Therefore 102 patients (51
per group) will be included (Figure 1).
A minimum time saving of 40 minutes would be
needed to change the manner of surgical preparation
towards the use of the LigaSure™ because of the high
costs of this device. A basic configuration for the use of
the LigaSure™ device costs nearly € 30.000, additionally
€ 260 per patient are the costs for the single use device
itself. The pilot trial with 14 patients by Gehrig et al.
showed a cost reduction of nearly € 800 per patient for
a operative time saving of 40 minutes (€ 500 for 30 min-
utes). Therefore we believe a time saving of at least 40
min would be needed to convince surgeons and hospital
managers to consider the purchase and use of this
equipment on a rugulary basis.
Eligibility
Inclusion criteria
￿ Clinical suspicion of a cancerous tumour on the head
of the pancreas, relied on imaging and laboratory values
￿ Aged 18 years or older




￿ Participation in another trial with interference of
outcome of this study
￿ Lack of compliance (assessed by the trial
investigator)
￿ Impaired mental state or language problems
(patient is not able to read German)
Subject withdrawal criteria
￿ At their own request or at request of the legal
representative
￿ If, in the investigator’s opinion (surgeon who per-
forms the dissection), continuation of the trial would
be detrimental to the subject’s well-being (e.g. bleed-
ing or other independent acute health problems)
All withdrawn patients will be reported in the final
results to guarantee maximum transparency.
Consent
The DISSECT- Trial will be conducted in accordance
with the protocol and in compliance with the moral, ethi-
cal, and scientific principles governing clinical research as
set out in the Declaration of Helsinki 1989 [16] and Good
Clinical Practice (http://www.ema.europa.eu/docs/
en_GB/document_library/Scientific_guideline/2009/09/
WC500002874.pdf). The protocol was approved by the
Ethics Committee of the University of Heidelberg (S-061/
2009). All Patients who are assigned the pp-Whipple pro-
cedure at the Department of General, Abdominal and
Transplant Surgery, University of Heidelberg, will be
screened for eligibility and informed about the DISSECT
trial during a visit prior to treatment. The study proce-
dure, risks, benefits and data management will be clari-
fied in detail before the patients are asked to give their
informed consent. After inclusion of the patient in the
study, his personal data (height (cm), weight (kg), gender,
Karnowsky-Index (0 - 100%), medication of immunsup-
pression, antibiotics (yes/no), chemotherapy (yes/no))
will be recorded into the CRF. (Table 1)
Randomization and procedures for minimizing bias
Minimizing systemic bias
To achieve comparable groups for known and unknown
risk factors randomization will be performed as
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sizes in a 1:1 allocation ratio. Allocation to treatment
group will be carried out by the randomization software
RITA
® [17]. Randomization numbers that become
vacant by withdrawal will be reused.
102 patients will be recruited according to the sam-
p l es i z ec a l c u l a t i o n .R a n d o mization will be performed
i n d e p e n d e n t l yb yas t u d yn u r s eo ft h eC l i n i c a lS t u d y
Center Surgery (KSC) to the conventional group or to
the LVSS group. Randomization will be carried out
after patient has signed the informed consent and will
be documented in the case report file of every patient.
Intervention will be scheduled 1-3 days after inclusion
depending on the earliest operation appointment
possible.
Minimizing treatment bias
A standardized operation technique will be used in both
groups. The same LigaSure™ device will be used in the
LVSS group. The physician responsible needs to have
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Figure 1 Flowchart according to CONSORT.
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Page 3 of 8will be trained and updated every three months to guar-
antee comparable treatment of patients.
Minimizing measurement bias
A study nurse will document and monitor the procedure in
the operating theatre. The patients are blinded for the used
operation technique. Physicians’ blinding is not possible
due to the different techniques used during the operation.
Study treatment
The surgical technique of PPW procedure is highly stan-
dardized in the surgical department and consists of the
following operative steps [12,13]: After mobilization of
the hepatic flexure of the colon, the duodenum and head
of the pancreas are separated from the retroperitoneal
bed (Kocher maneuver). The gallbladder is removed and
the bile duct is divided above the cystic duct entry across
the common hepatic duct. Next, the portal vein is
exposed. After division of the right gastric artery, the gas-
troduodenal artery and gastroepiploic vessels, the duode-
num distal to the pylorus is divided. The pancreas is
transected in front of the portal vein using a scalpel and
not with the Ligasure Impact™ device. Dissection of the
distal duodenum proximal to the ligament of Treitz is
then performed. This is followed by the reconstruction
phase, with preparation and resection of the proximal 10-
15 cm section of the jejunum at a point that will provide
sufficient mobility of the jejunum to reach the right
upper quadrant after it is brought through the transverse
mesocolon for the biliary and pancreatic anastomosis.
Pancreatojejunostomy is performed with two layers, end-
to-side, after mobilization of the pancreatic stump. The
end-to-side hepatojejunostomy is made with a single
layer and is placed about 10-15 cm aboral of the pancrea-
tojejunostomy. Finally, an end-to-side duodenojejunost-
omy with two layers is performed about 50 cm distal to
the pancreatojejunostomy in an antecolic position.
Experimental group
In the LVSS group, dissection and hemostasis of vessels
with a diameter of up to seven millimeters (Figure 2) as
well as bowel transection (Figure 3) will be performed
with the Ligasure Impact™ device (Valleylab™, Boulder,
Colorado, USA). For safety reasons, the transected
bowel will be overstitched and larger vessels will be
ligated in the LVSS group.
Control group
In the conventional group, scissors, ligatures, clips and
sutures will be used for dissection and hemostasis.
Transection of the small bowel will be done with a Lin-
ear Cutter 55 2.0 mm (Ethicon Endo-Surgery, Inc.,
USA).
Primary and secondary endpoints
Primary endpoint
The primary endpoint will be the operating time of the
randomized dissection technique.
Definition of the primary endpoint:






Visit 1 (day 30post OP ) by
phone
Visit 2-8 (European Pancreas
Center)
Past medical history* X
Informed consent X
Personal data** X
Examination of primary endpoints:
Operating time X
Examination of primary endpoints:
Mortality X X X
Peri- and postoperative complications X X X
Re-intervention X X
Intraoperative blood loss X
Hospital stay X
Reuptake XX
Time of anesthesia pre- and
postoperative
X
Intraoperative material consumption X
Local recurrence X
Quality of life X X
Safety criteria AE, SAE (2.6) X X X
* study-relevant past medical history, past surgical history
** height (cm), weight (kg), gender, Karnowsky-Index, medication of immunsuppresion, antibiotics, chemotherapy
Gehrig et al. Trials 2011, 12:162
http://www.trialsjournal.com/content/12/1/162
Page 4 of 8The operation time will be measured from the begin-
n i n go ft h es u r g i c a lp r o c e d u r e( i n c i s i o no ft h es k i n )t o
the end of the surgical procedure (closure of the skin).
It will be documented in the operation log.
Assessment of the primary endpoint:
The operating time will be assessed postoperatively in
the case report file (CRF) by the physician responsible
and will be confirmed by an independent study nurse. A




○ Perforation of hollow organs (stomach, small
intestine, colon, gallbladder/biliary tract)






○ Postoperative pancreatic fistula (POPF)
○ Intraabdominal abscess
○ Anastomotic leakage of the
choledochojejunostomy
○ Anastomotic leakage of the gastrojejunostomy
￿ Re-intervention (operational/interventional)
￿ Intraoperative blood loss
￿ Hospital stay
￿ Re-hospitalization-rate (30 days postoperative)
￿ Duration of anesthesia
￿ Intraoperative material consumption
￿ Material costs, calculated by the material
consumption
￿ Overall costs of the operation, calculated by the
indirect and direct costs during the hospital stay and
the costs accumulated 30 days postoperatively
￿ Local recurrence of disease
￿ Quality of life analysed in questionnaires (EORTC
QLQ-C30, EORTC QLQ PAN26, special question-
naire of the European Pancreas Center, University of
Heidelberg)
￿ Mortality rate
Definitions of secondary endpoints are shown in Table 2.
Assessment:
1. Perioperative complications of the pp-Whipple
procedure will be recorded on the day of operation
by an independent study nurse.
2. Postoperative complications of the pp-Whipple
procedure will be recorded in patients’ discharge
data and on visit 1 (30 days after operation) after a
standardized telephone interview by a study nurse. A
confirmation by the patient’s family physician will be
requested following any abnormality reported by the
patient. The following standard aftercare takes place
initially twice quarterly (visit 2, 3 months after
operation; visit 3, 6 months after operation) then
half-yearly for two years (visit 4, 12 months after
operation; visit 5, 18 months after operation; visit 6,
24 months after operation; visit 7, 30 months after
operation and visit 8, 36 months after operation)
with a clinical examination, imaging (ultrasound,
CT, MRT), general and standardized questionnaires
(EORTC-QLQ-C30, EORTC-QLQ-PAN26 and a
special questionnaire from the European Pancreas
Center) and laboratory value control in the Eur-
opean Pancreas Center at the surgical department.
Safety aspects
Specification of safety variables
Training for surgeons In each operation there will be a
surgeon (senior surgeon) who has experience of at least
Figure 2 Dissection with the LVSS in pylorus-preserving
pancreatoduodenectomy.
Figure 3 Transection of the proximal duodenum with the LVSS.
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Bleeding Severe intraoperative bleeding Mentioned in operation report
Perforation of hollow
organs
Perforation of stomach, small intestine,
colon or biliary tract/gallbladder










postoperative bleeding Need for more than 2 units of red blood cells within 24 hours after surgery
OR
Need of surgical treatment (mentioned in re-operation report)
Hemtoma Radiological (ultrasound, CT) findings positive for reoperation or reopening of the
wound
wound infection Deep and/or superficial according to CDC definition [20]
Gastroparesis delayed gastric emptying (DGE) Consensus definition of delayed gastric emptying after pancreatic surgery of the
International Study Group of Pancreatic Surgery (ISGPS) [21]
pp-Whipple specific
complications
postoperative pancreatic fistula (POPF) Drain output of any measurable volume of fluid on or after postoperative day 3
with an amylase content greater than 3 times the serum amylase activity. Three
different grades of POPF (grades A, B, C) are defined according to the clinical
impact on the patient’s hospital course [22]
Intraabdominal abscess Intraabdominal collection of purulent or infected fluids (positiv bacterial culture)




Bilirubin-rich (more than 5000 units) drainage fluid of more than 50 ml per day
on or after the 10th postoperative day
OR
Mentioned in re-operation report
anastomotic leakage of
gastrojejunostomy
Radiological findings correlating to gastrojejunostomy insufficiency (e.g. CT with




Re-intervention operational Reoperation due to any cause
interventional Interventional haemostasis or drainages due to any cause
Intraoperative blood
loss
Mentioned in operation report
Hospital stay Time of admission to discharge
Re-hospitalization-rate Re- hospilization within 30 days after surgery due to any cause
Duration of anesthesia Mentioned in anesthesia report
Intraoperative material
consumption
All materials, which are necessary for surgery
Material costs Costs, which occurs due to the material consumption during the surgery




Radiological (ultrasound, CT) findings positive for recurrence of disease
Quality of life EORTC QLQ-C30, EORTC QLQ PAN26 and special questionnaire of the European
Pancreas Center Heidelberg on day 30 (±10days), 90 (±10 days), 180 (±10 days), 1
year (± 1 month), 1,5 years (± 1 month), 2 years (± 1 month), 2,5 years (± 1
month) and 3 years (± 1 month)
Mortality rate Death to any course until year 3 after operation
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Page 6 of 8100 pp-Whipple procedures. The operation will be car-
ried out as a standard procedure; the LigaSure™ device
has been used in the department for several years
already.
Concomitant medication Concomitant medication will
not be recorded because the primary operating time of
the two dissection techniques is a local and technical
endpoint. Therefore, a systemic pharmacological interac-
tion with the medication of the patient will be very
unlikely.
Past medical history Prior and concomitant illness of
the patients will be documented in the CRF. The cate-
gory of the primary disease (reason for pp-Whipple pro-
cedure) is one of the variables to be analyzed for
baseline comparability.
Adverse events and serious adverse events AEs will be
reported to the principal investigator in regular intervals
during the course of the study and will be documented
in the CRF. It is necessary to note the date, the symp-
toms, beginning and end, treatment, severity (mild,
moderate, severe) and the context of the operation
(except those events detected in the endpoints).
SAEs which meet one of the definitions of the second-
ary endpoints are treated as SAEs regarding their docu-
mentation but do not have to be reported to the sponsor
(Covidien GmbH, Germany) and principal investigator
(Prof. Dr. MW Büchler, Chairman of the Department of
General, Visceral and Transplantation Surgery, Univer-
sity Hospital of Heidelberg) within 24 hours. They will be
reported to the principal investigator in regular intervals
throughout the study. The surgical trial coordinator will
also cross-check the SAEs/AEs of all patients.
Analysis
Comparisons will be made of the primary endpoints of
both intervention groups for all randomized patients
who underwent surgery involving the pp-Whipple pro-
cedure. Patients will be analysed as randomized applying
the ITT principle [18]. In addition, a per-protocol analy-
sis will be performed, including patients who are strictly
treated according to the study protocol.
The outcome measures of the primary endpoint will
be tested confirmatory applying an analysis of covar-
iance with treatment as factor and age and BMI as con-
tinuous covariates.
Secondary endpoints will be analysed in a descriptive
manner. Graphically methods will be used by means of
box- and scatter- plots. For all continuous secondary
endpoints a t-test will be applied, possible differences of
categorical secondary endpoints will be analysed using
chi-square tests. All p-values will be used as descriptive
statistics only without any confirmatory value.
The secondary endpoint Quality of Life (EORTC QLQ-
C30, EORTC QLQ PAN26) will be anlysed by an
application of analysis of covariance that adjusts for age
and EORTC QLQ-C30, EORTC QLQ PAN26 before
surgery.
The following procedure will be applied for missing
data:
If at least half of the items from the scale have been
answered, the missing items are replaced by the average
of those items that are not missing (calculated average
rounded to the nearest integer). If less than half of the
items from the scale have been answered, the scale is
set to missing [19].
If it is evident that missing items or missing scales are
related to a worsening in physical functioning, the missing
values are replaced by the worst value measured in the
respective intervention group at the respective time point.
The average EORTC QLQ-C30, EORTC QLQ PAN26
score can be calculated, if at least one measurement at
day 30 (±10days), 90 (±10 days), 180 (±10 days), 1 year
(± 1 month), 1,5 years (± 1 month), 2 years (± 1
month), 2,5 years (± 1 month) or 3 years (± 1 month)
after surgery is available; if no measurement of the
EORTC QLQ-C30 or EORTC QLQ PAN26 after sur-
gery is available, the secondary endpoint is missing and
the patient is therefore not included into the analysis.
All statistical analyses will be performed using SAS
®
software, Version 9.1 (or higher) of the SAS System for
Unix (SAS Institute Inc., Cary, NC, USA).
Study organization
After approval of the protocol by the local ethics com-
mittee of the University of Heidelberg, the trial was
internationally registered at Germanctr.de
(DRKS00000166). All patients scheduled for a pp-Whip-
ple procedure in the Department of General, Visceral
and Transplantation Surgery, University Hospital of Hei-
delberg, will be referred to and screened by members of
the Clinical Study Center Surgery (KSC). The results of
the screening will be recorded in the screening-log.
Approximately 300 patients per year undergo a pp-
Whipple procedure in the Department of General, Visc-
eral and Transplantation Surgery, University Hospital of
Heidelberg. The estimated time frame to randomize 102
patients will be approximately 15 months.
The sponsor of the DISSECT trial is Covidien GmbH
(Germany).
The independent data management and statistical ana-
lysis will be carried out by the Institute of Medical Bio-
metry and Informatics (IMBI) of the University of
Heidelberg according to a prespecified Statistical Analy-
sis Plan. It controls the completeness and correctness of
the CRF as well as the administration.
The principal investigator has the right to terminate
the trial and to remove all trial material from the trial
centre at any time in consultation with the Clinical
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Page 7 of 8Study Team Leader and the Biostatistician. Reasons that
may require a termination of the trial include the fol-
lowing:
￿ The incidence or severity of adverse events in the
trial indicates a potential health hazard caused by
the study treatment
￿ It appears that the patient’s enrolment is unsatis-
factory with respect to quality or quantity or data
recording is severely inaccurate or incomplete
￿ External evidence that renders the necessity to ter-
minate the trial
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